Description

Sermorelin – 10 mg

(Growth Hormone Releasing Hormone Analog – GHRH 1-29)

Sermorelin is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH 1–29), corresponding to the biologically active fragment of endogenous GHRH. It acts on the pituitary somatotroph cells to stimulate natural, pulsatile release of growth hormone (GH) through activation of the GHRH receptor.

Sermorelin has been extensively investigated in research settings as a physiological GH secretagogue, providing a naturalistic alternative to exogenous GH administration. Its short half-life and pulsatile stimulation make it a valuable compound for studying endocrine regulation, growth mechanisms, and metabolic signaling in experimental models.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• GHRH receptor activation: Binds to GHRH-R on pituitary somatotrophs, triggering GH synthesis and secretion.

• Physiologic GH pulsatility: Stimulates natural rhythmic GH release that promotes downstream IGF-1 production.

• Synergistic effects: Demonstrates amplified GH output when co-administered with GHRPs (e.g., GHRP-2, Ipamorelin).

• Metabolic influence: Supports anabolic processes, cellular recovery, and lipid metabolism in research systems.

• Neuroendocrine modulation: Regulates hypothalamic–pituitary feedback loops associated with aging and metabolism.

---

Potential Benefits (Based on Preclinical Research):

• Enhanced endogenous GH and IGF-1 production

• Improved muscle repair and tissue regeneration

• Support for metabolic balance and lipid utilization

• Studied for age-related GH decline and neuroendocrine health

• Applications in research involving pituitary function and anabolic regulation

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.